Market capitalization | CHF140.88m |
Enterprise Value | CHF176.19m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 26.34 |
P/S ratio (TTM) P/S ratio | 21.06 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -22.30% |
Revenue (TTM) Revenue | CHF6.69m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Newron Pharmaceutical:
1 Analyst has issued a forecast Newron Pharmaceutical:
Jun '24 |
+/-
%
|
||
Revenue | 6.69 6.69 |
22%
22%
|
|
Gross Profit | 6.50 6.50 |
-
|
|
EBITDA | -14 -14 |
32%
32%
|
EBIT (Operating Income) EBIT | -14 -14 |
32%
32%
|
Net Profit | -18 -18 |
17%
17%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
Head office | Italy |
CEO | Stefan Weber |
Founded | 2002 |
Website | www.newron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.